László Nemes

2.5k total citations
59 papers, 1.7k citations indexed

About

László Nemes is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, László Nemes has authored 59 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 16 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in László Nemes's work include Hemophilia Treatment and Research (44 papers), Platelet Disorders and Treatments (21 papers) and Blood Coagulation and Thrombosis Mechanisms (16 papers). László Nemes is often cited by papers focused on Hemophilia Treatment and Research (44 papers), Platelet Disorders and Treatments (21 papers) and Blood Coagulation and Thrombosis Mechanisms (16 papers). László Nemes collaborates with scholars based in Hungary, United Kingdom and Italy. László Nemes's co-authors include Peter W. Collins, F. Baudo, Paul Knoebl, Lilian Tengborn, Fabio Pellegrini, Pascual Marco, Angela Huth‐Kühne, H. Lévesque, H. Lévesque and Paul Giangrande and has published in prestigious journals such as Blood, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

László Nemes

55 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
László Nemes Hungary 18 1.5k 563 132 72 69 59 1.7k
Frank G. H. Hill United Kingdom 14 744 0.5× 162 0.3× 130 1.0× 73 1.0× 9 0.1× 24 1.0k
Betty Cheung United Kingdom 4 483 0.3× 383 0.7× 134 1.0× 47 0.7× 9 0.1× 8 868
José Villagra United States 5 233 0.2× 231 0.4× 73 0.6× 32 0.4× 17 0.2× 6 501
Ida Carmosino Italy 15 587 0.4× 327 0.6× 231 1.8× 37 0.5× 20 0.3× 83 822
Martine Escoffre France 15 759 0.5× 250 0.4× 165 1.3× 26 0.4× 58 0.8× 24 864
Alessio Perrotti Italy 10 387 0.3× 189 0.3× 32 0.2× 50 0.7× 7 0.1× 36 685
A Feldges Switzerland 13 348 0.2× 107 0.2× 135 1.0× 63 0.9× 17 0.2× 30 1.0k
Hassan Sibai Canada 11 226 0.1× 118 0.2× 87 0.7× 22 0.3× 33 0.5× 69 369
TR Kinney United States 8 653 0.4× 534 0.9× 38 0.3× 62 0.9× 18 0.3× 11 831
Frank G. Keller United States 10 208 0.1× 74 0.1× 50 0.4× 48 0.7× 21 0.3× 26 425

Countries citing papers authored by László Nemes

Since Specialization
Citations

This map shows the geographic impact of László Nemes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by László Nemes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites László Nemes more than expected).

Fields of papers citing papers by László Nemes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by László Nemes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by László Nemes. The network helps show where László Nemes may publish in the future.

Co-authorship network of co-authors of László Nemes

This figure shows the co-authorship network connecting the top 25 collaborators of László Nemes. A scholar is included among the top collaborators of László Nemes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with László Nemes. László Nemes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sidonio, Robert F., et al.. (2025). Individualizing dosing frequency may improve the efficacy of prophylaxis in patients with von Willebrand disease—a WIL-31 subanalysis. Research and Practice in Thrombosis and Haemostasis. 9(7). 103221–103221. 1 indexed citations
2.
Sidonio, Robert F., Ana Boban, Adlette Inati, et al.. (2024). von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease. Blood Advances. 8(6). 1405–1414. 10 indexed citations
3.
Castaman, Giancarlo, et al.. (2024). Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B. Scientific Reports. 14(1). 20534–20534.
4.
Gindele, Réka, et al.. (2024). Clinical and Molecular Characterization of Nine Novel Antithrombin Mutations. International Journal of Molecular Sciences. 25(5). 2893–2893.
5.
Ay, Cihan, Maria Elisa Mancuso, Davide Matino, et al.. (2024). Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal. Research and Practice in Thrombosis and Haemostasis. 8(2). 102363–102363. 1 indexed citations
6.
Zápotocká, Ester, Angelika Bátorová, Ernest Bilić, et al.. (2022). First experience of a hemophilia monitoring platform: florio HAEMO. Research and Practice in Thrombosis and Haemostasis. 6(2). e12685–e12685. 3 indexed citations
7.
Giangrande, Paul, et al.. (2020). Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2. Journal of Thrombosis and Haemostasis. 18. 5–14. 20 indexed citations
8.
Orosz, Zsuzsanna, Helga Bárdos, Amir H. Shemirani, et al.. (2019). Cellular Factor XIII, a Transglutaminase in Human Corneal Keratocytes. International Journal of Molecular Sciences. 20(23). 5963–5963. 6 indexed citations
9.
Tiede, Andreas, Paul Giangrande, Jerome Teitel, et al.. (2019). Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement. Haemophilia. 25(6). 969–978. 27 indexed citations
10.
Gruppo, Ralph A., Daniel R Malan, J. Kapocsi, et al.. (2018). Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Journal of Thrombosis and Haemostasis. 16(10). 1984–1993. 17 indexed citations
11.
Gindele, Réka, György Pfliegler, László Nemes, et al.. (2017). Clinical and laboratory characteristics of antithrombin deficiencies: A large cohort study from a single diagnostic center. Thrombosis Research. 160. 119–128. 16 indexed citations
12.
Nemes, László, Víctor Jiménez‐Yuste, L. Rusen, et al.. (2015). Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Thrombosis and Haemostasis. 114(10). 676–684. 6 indexed citations
13.
Knoebl, Paul, Pascual Marco, F. Baudo, et al.. (2012). Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Journal of Thrombosis and Haemostasis. 10(4). 622–631. 326 indexed citations
14.
Nemes, László, H. Pöllmann, & Thomas Becker. (2012). Interim data on long‐term efficacy, safety and tolerability of a plasma‐derived factor VIII concentrate in 109 patients with severe haemophilia A. Haemophilia. 18(4). 496–502. 6 indexed citations
15.
Tengborn, Lilian, F. Baudo, Angela Huth‐Kühne, et al.. (2012). Pregnancy‐associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG An International Journal of Obstetrics & Gynaecology. 119(12). 1529–1537. 81 indexed citations
16.
Paula, Erich Vinícius De, Kaan Kavaklı, Johnny Mahlangu, et al.. (2011). Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. Journal of Thrombosis and Haemostasis. 10(1). 81–89. 24 indexed citations
17.
18.
19.
Petrini, Pia, Hérvè Chambost, & László Nemes. (2004). Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary. Haemophilia. 10(s4). 94–96. 20 indexed citations
20.
Holló, Péter, et al.. (2003). Linear IgA dermatosis associated with chronic clonal myeloproliferative disease. International Journal of Dermatology. 42(2). 143–146. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frank G. H. Hill Breakdown of academic impact, for papers by Betty Cheung Breakdown of academic impact, for papers by José Villagra Breakdown of academic impact, for papers by Ida Carmosino Breakdown of academic impact, for papers by Martine Escoffre Breakdown of academic impact, for papers by Alessio Perrotti Breakdown of academic impact, for papers by A Feldges Breakdown of academic impact, for papers by Hassan Sibai Breakdown of academic impact, for papers by TR Kinney Breakdown of academic impact, for papers by Frank G. Keller
Rankless by CCL
2026